Rep. Peter Roskam (R-IL), chairman of the Health Subcommittee on Ways and Means, today stressed the need for Congress to reduce certain regulations on providers that “have no relationship to patient health.” 
 
The AHA has laid out actions that Congress could take to immediately reduce the regulatory burden on hospitals, health systems and the patients they serve. The proposals range from cancelling Stage 3 meaningful use requirements for electronic health records to permanently prohibiting the enforcement of direct supervision requirements in critical access and small or rural hospitals.  
 
Roskam also said that Congress is eager to hear hospital and health system leaders’ opinions on how to handle the opioid epidemic.  
 
“The institutions that you’re leading are right at the center of this, and you have a disproportionately positive influence in this debate,” Roskam said.

[For additional highlights from the AHA Annual Membership meeting, click here.] 

Roskam also addressed the issue of drug pricing, mentioning that President Trump will make an announcement in the next few days that will help “frame the debate moving forward” on the issue. 
 
“We’re not going to stay where we are,” Roskam said. “The place that we are is just completely unsatisfying.”

Related News Articles

Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
The Centers for Medicare & Medicaid Services today released a notice seeking public comment on the collection of information request regarding the State…
Perspective
Public
We look forward to welcoming hospital and health system leaders to our 2025 AHA Annual Membership Meeting in Washington, D.C., in less than two months.While…
Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…